广州达安基因股份有限公司2024年度股东会决议公告

Meeting Overview - The 2024 Annual General Meeting (AGM) of Guangzhou Da'an Gene Co., Ltd. was held on April 18, 2025, combining on-site and online voting methods [4][5] - A total of 593 shareholders and authorized representatives attended the meeting, representing 457,340,573 shares, which is 32.5870% of the total shares [6] Voting Results - The following proposals were approved during the meeting: - The 2024 Board of Directors Work Report received 99.2868% approval [8] - The 2024 Supervisory Board Work Report received 99.2783% approval [9] - The 2024 Financial Settlement Proposal received 99.2832% approval [10] - The 2024 Annual Report and its summary received 99.2876% approval [11] - The 2024 Profit Distribution Proposal received 99.2409% approval, with 74.1529% approval from minority investors [12] - The proposal for expected related party transactions for 2025 received 76.2190% approval [13] - The proposal for cash management using idle funds for 2025 received 99.2478% approval, with 74.3882% approval from minority investors [14] - The proposal regarding the termination of stock listing for a subsidiary received 99.3168% approval [15] Independent Directors' Report - Independent directors provided a detailed report on their activities during 2024, including attendance at board meetings and efforts to protect minority investors' rights [16] Legal Opinion - The meeting was witnessed by lawyers from Beijing Kangda (Guangzhou) Law Firm, who confirmed that the meeting's procedures and resolutions complied with relevant laws and regulations [17][18] Documentation - The resolutions from the AGM and the legal opinion from the law firm are available for review [19]